JP2011507880A - 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤 - Google Patents

慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤 Download PDF

Info

Publication number
JP2011507880A
JP2011507880A JP2010539775A JP2010539775A JP2011507880A JP 2011507880 A JP2011507880 A JP 2011507880A JP 2010539775 A JP2010539775 A JP 2010539775A JP 2010539775 A JP2010539775 A JP 2010539775A JP 2011507880 A JP2011507880 A JP 2011507880A
Authority
JP
Japan
Prior art keywords
combination
combination according
nilotinib
nitrogen mustard
cll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010539775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507880A5 (cg-RX-API-DMAC7.html
Inventor
ラケル・シルビア・アロイス
ローレンス・カール・パナシ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2011507880A publication Critical patent/JP2011507880A/ja
Publication of JP2011507880A5 publication Critical patent/JP2011507880A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010539775A 2007-12-21 2008-12-18 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤 Pending JP2011507880A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1570407P 2007-12-21 2007-12-21
PCT/US2008/087336 WO2009082662A1 (en) 2007-12-21 2008-12-18 Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014115061A Division JP2014177487A (ja) 2007-12-21 2014-06-03 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤

Publications (2)

Publication Number Publication Date
JP2011507880A true JP2011507880A (ja) 2011-03-10
JP2011507880A5 JP2011507880A5 (cg-RX-API-DMAC7.html) 2012-01-26

Family

ID=40352369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010539775A Pending JP2011507880A (ja) 2007-12-21 2008-12-18 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
JP2014115061A Pending JP2014177487A (ja) 2007-12-21 2014-06-03 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014115061A Pending JP2014177487A (ja) 2007-12-21 2014-06-03 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤

Country Status (7)

Country Link
US (2) US20110028422A1 (cg-RX-API-DMAC7.html)
EP (1) EP2240172B1 (cg-RX-API-DMAC7.html)
JP (2) JP2011507880A (cg-RX-API-DMAC7.html)
ES (1) ES2459877T3 (cg-RX-API-DMAC7.html)
PL (1) PL2240172T3 (cg-RX-API-DMAC7.html)
PT (1) PT2240172E (cg-RX-API-DMAC7.html)
WO (1) WO2009082662A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
CA2941632C (en) * 2014-03-13 2023-10-24 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
US9777572B2 (en) * 2014-11-17 2017-10-03 Baker Hughes Incorporated Multi-probe reservoir sampling device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060122186A1 (en) * 2002-11-12 2006-06-08 Panasci Lawrence C Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060122186A1 (en) * 2002-11-12 2006-06-08 Panasci Lawrence C Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013028084; N ENGL J MED Vol.354,No.24, 2006, p.2542-2551 *
JPN6013028086; 医学のあゆみ Vol.220,No.9, 200703, p.675-680 *
JPN6013028088; 血液・腫瘍科 Vol.55,No.5, 200711, p.521-529 *

Also Published As

Publication number Publication date
ES2459877T3 (es) 2014-05-12
PT2240172E (pt) 2014-05-28
JP2014177487A (ja) 2014-09-25
US20110028422A1 (en) 2011-02-03
WO2009082662A1 (en) 2009-07-02
EP2240172A1 (en) 2010-10-20
PL2240172T3 (pl) 2014-08-29
EP2240172B1 (en) 2014-03-19
US20150051236A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
WO2022182857A1 (en) Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
JP2023515817A (ja) ダブラフェニブ、erk阻害剤及びshp2阻害剤を含む三重の医薬品の組合せ
US8492383B2 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
US20020156023A1 (en) Lometrexol combination therapy
UA125216C2 (uk) Комбінована терапія
JP2014177487A (ja) 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
US20190290627A1 (en) Pim kinase inhibitor combinations
EP3010505A1 (en) Pharmaceutical combinations
KR20200036880A (ko) 3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물
US20100008923A1 (en) Organic Compounds
JP2022514056A (ja) 癌の治療に使用するためのRaf阻害剤及びCDK4/6阻害剤による組み合わせ療法
JP2023524789A (ja) Tno155及びナザルチニブを含む医薬組合せ
JP2022518974A (ja) ブルトン型チロシンキナーゼ阻害剤の投薬
EP1496908B1 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
JP2006504727A (ja) 多発性骨髄腫の処置のためのラクトン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140204